Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in Germany / NCT07817043
Starting soon Observational

Microbiology Operations & Time Optimization in Sepsis

NCT07817043 · tracked via the Priya Life Science Germany tracker
Sponsor
University Medicine Greifswald
Phase
Observational
Started
2026-10-01
Last updated
2026-09-14

Condition(s) studied

SepsisBloodstream InfectionBacterial InfectionsSeptic ShockBacteremia

Investigational drug(s) / intervention(s)

laboratory infrastructure

laboratory infrastructure: will follow

Study summary

The goal of this study is to simulate turn-around times of blood cultures from blood culture collection to final communication of the result. The main objective is to develop a web-based tool that is able to simulate heterogeneous laboratory settings and to analyse the impact of infrastructure and opening hours on blood culture turn-around times.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
microbiological laboratories conducting blood culture analysis

Primary outcome measure(s)

  • Turn-around time — 4 weeks for the conduction of the simulation

Trial sites (1)

FacilityCityRegionStatus
University Medicine Greifswald Greifswald Germany

More University Medicine Greifswald trials in Germany

Acupuncture Mechanism in Relief of Gag Reflex Recruiting
Prognostic Value of Different Nutritional Screening Tools in Acute Pancreatitis Active, not recruiting
Transcranial Direct Current Stimulation to Enhance Training Effectiveness in Chronic Post-Stroke Aphasia Active, not recruiting
Cognitive Training and Brain Stimulation in Women With Post-chemotherapy Cognitive Impairment Recruiting
A Comparison of Fisetin Kinetics in Young and Old Adults Recruiting

Other trials for the same condition

Remote Ischemic Preconditioning in Septic Patients Recruiting
Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock Recruiting
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy Recruiting
Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis Recruiting
Fosfomycin I.v. for Treatment of Severely Infected Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07817043 on ClinicalTrials.gov ↗ ← All trials in Germany